VERICEL CORPORATION

VCEL · NASDAQ

Biological Product (except Diagnostic) Manufacturing · US

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.

Market Data

Price $33.40 -0.72 (-2.11%)

Market Cap$1.57B

P/E Ratio95.16

EPS$—

52W High$50.36

52W Low$29.24

Beta1.18

Data from Finnhub · Updated Mar 11, 2026